Phase 1 Trial of a Therapeutic Anti–Yellow Fever Virus Human Antibody
Copyright © 2020 Massachusetts Medical Society. BACKGROUND Insufficient vaccine doses and the lack of therapeutic agents for yellow fever put global health at risk, should this virus emerge from sub-Saharan Africa and South America. METHODS In phase 1a of this clinical trial, we assessed the safety,...
Main Authors: | Low, Jenny G, Ng, Justin HJ, Ong, Eugenia Z, Kalimuddin, Shirin, Wijaya, Limin, Chan, Yvonne FZ, Ng, Dorothy HL, Tan, Hwee-Cheng, Baglody, Anjali, Chionh, Yok-Hian, Lee, Debbie CP, Budigi, Yadunanda, Sasisekharan, Ram, Ooi, Eng-Eong |
---|---|
Other Authors: | Singapore-MIT Alliance in Research and Technology (SMART) |
Format: | Article |
Language: | English |
Published: |
Massachusetts Medical Society
2022
|
Online Access: | https://hdl.handle.net/1721.1/133594.2 |
Similar Items
-
Phase 1 Trial of a Therapeutic Anti–Yellow Fever Virus Human Antibody
by: Low, Jenny G, et al.
Published: (2021) -
Minding the “T”s beyond the “B”s: Shaping vaccines for future pandemics
by: Shirin Kalimuddin, et al.
Published: (2023-11-01) -
Minding the "T"s beyond the "B"s: Shaping vaccines for future pandemics.
by: Shirin Kalimuddin, et al.
Published: (2023-11-01) -
Chronic sequelae complicate convalescence from both dengue and acute viral respiratory illness
by: Kalimuddin, Shirin, et al.
Published: (2023) -
Early peripheral blood MCEMP1 and HLA-DRA expression predicts COVID-19 prognosisResearch in context
by: Kuan Rong Chan, et al.
Published: (2023-03-01)